|
US6346614B1
(en)
*
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
ATE385237T1
(de)
|
1999-02-26 |
2008-02-15 |
Univ British Columbia |
Antisense-therapie für trpm-2
|
|
US7569551B2
(en)
|
2000-02-25 |
2009-08-04 |
The University Of British Columbia |
Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
|
|
ATE450621T2
(de)
|
2000-03-30 |
2009-12-15 |
Whitehead Biomedical Inst |
Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
KR100872437B1
(ko)
|
2000-12-01 |
2008-12-05 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
|
|
EP1465995B1
(en)
*
|
2002-01-17 |
2008-07-30 |
The University of British Columbia |
Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
EP1667731B1
(en)
*
|
2003-10-01 |
2013-05-22 |
The University Of British Columbia |
Bispecific oligonucleotide for the treatment of cns malignancies
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
WO2005094899A1
(en)
|
2004-04-02 |
2005-10-13 |
The University Of British Columbia |
Clusterin antisense therapy for treatment of cancer
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
PL1766010T3
(pl)
|
2004-06-28 |
2011-07-29 |
Univ Western Australia |
Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
|
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
|
US20060166234A1
(en)
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
|
PT1814595E
(pt)
*
|
2004-11-23 |
2014-04-02 |
Univ British Columbia |
Tratamento de cancro com uma combinação de um agente que perturba a via de sinalização egf e um oligonucleótido que reduz os níveis de clusterina
|
|
JP5713377B2
(ja)
|
2005-12-28 |
2015-05-07 |
ザ スクリプス リサーチ インスティテュート |
薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
|
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
WO2007139943A2
(en)
*
|
2006-05-26 |
2007-12-06 |
Ico Therapeutics Inc. |
Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders
|
|
JP6047270B2
(ja)
|
2006-08-11 |
2016-12-21 |
バイオマリン テクノロジーズ ベー．フェー． |
Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
|
|
US8809514B2
(en)
|
2006-09-22 |
2014-08-19 |
Ge Healthcare Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
|
|
CN103212085A
(zh)
|
2007-07-12 |
2013-07-24 |
普罗森那技术公司 |
用于使化合物靶向多种选定器官或组织的分子
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2203173B1
(en)
|
2007-10-26 |
2015-12-23 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
WO2009099326A1
(en)
|
2008-02-08 |
2009-08-13 |
Prosensa Holding Bv |
Methods and means for treating dna repeat instability associated genetic disorders
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
CA2739464C
(en)
|
2008-10-03 |
2020-03-31 |
Curna, Inc. |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
CA2741294C
(en)
*
|
2008-10-24 |
2018-04-24 |
Isis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
|
CN105779453A
(zh)
|
2008-10-24 |
2016-07-20 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
KR101829469B1
(ko)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
|
|
KR101866152B1
(ko)
|
2008-12-04 |
2018-06-08 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
MX2011005912A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
|
|
WO2010093904A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
EP2408919B1
(en)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
EP2408920B1
(en)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
|
EP2421971B1
(en)
|
2009-04-24 |
2016-07-06 |
BioMarin Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
WO2010129861A2
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
WO2010135329A2
(en)
|
2009-05-18 |
2010-11-25 |
Curna, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
|
CN102549158B
(zh)
|
2009-05-22 |
2017-09-26 |
库尔纳公司 |
通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
|
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
|
CN102612560B
(zh)
|
2009-06-16 |
2017-10-17 |
库尔纳公司 |
通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
|
|
US8859515B2
(en)
|
2009-06-24 |
2014-10-14 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
|
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
|
WO2011005779A2
(en)
|
2009-07-07 |
2011-01-13 |
University Of Southern California |
Biomarkers for the early detection of autoimmune diseases
|
|
US20120252869A1
(en)
|
2009-07-24 |
2012-10-04 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
JP6128848B2
(ja)
|
2009-08-05 |
2017-05-17 |
クルナ・インコーポレーテッド |
インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
|
|
CA2770104C
(en)
|
2009-08-11 |
2019-03-19 |
Opko Curna, Llc |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
|
KR101892760B1
(ko)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
|
|
KR101802540B1
(ko)
|
2009-09-25 |
2017-11-28 |
큐알엔에이, 인크. |
Ｆｌｇ의 발현 및 활성을 조절함으로써 필라그린(ｆｌｇ)에 관련된 질환의 치료
|
|
BR122023023194A2
(pt)
|
2009-11-12 |
2023-12-26 |
The University Of Western Australia |
Oligonucleotídeo antissentido, composição e respectivo uso
|
|
WO2011084455A2
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc. |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
|
ES2661387T3
(es)
|
2009-12-23 |
2018-03-28 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
|
|
JP6031356B2
(ja)
|
2009-12-23 |
2016-11-24 |
カッパーアールエヌエー，インコーポレイテッド |
Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
|
|
KR101838305B1
(ko)
|
2009-12-29 |
2018-03-13 |
큐알엔에이, 인크. |
ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
|
|
US8962585B2
(en)
|
2009-12-29 |
2015-02-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
|
DK2519632T3
(en)
|
2009-12-31 |
2018-07-23 |
Curna Inc |
TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
|
|
EP2521784B1
(en)
|
2010-01-04 |
2017-12-06 |
CuRNA, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
|
CN102822342B
(zh)
|
2010-01-06 |
2017-05-10 |
库尔纳公司 |
通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
|
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
|
CN102782135A
(zh)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
|
|
WO2011103528A2
(en)
|
2010-02-22 |
2011-08-25 |
Opko Curna Llc |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
|
CA2787673A1
(en)
|
2010-03-01 |
2011-09-09 |
Tau Therapeutics Llc |
Cancer diagnosis and imaging
|
|
WO2011112516A1
(en)
*
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
|
KR101900962B1
(ko)
|
2010-04-09 |
2018-09-20 |
큐알엔에이, 인크. |
섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
|
|
WO2011139387A1
(en)
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
CA2799207C
(en)
|
2010-05-26 |
2019-03-26 |
Curna, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
|
RU2620978C2
(ru)
|
2010-05-26 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra
|
|
KR101914309B1
(ko)
|
2010-06-23 |
2018-11-02 |
큐알엔에이, 인크. |
전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
|
|
NO2593547T3
(enExample)
|
2010-07-14 |
2018-04-14 |
|
|
|
CA2813901C
(en)
|
2010-10-06 |
2019-11-12 |
Curna, Inc. |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
|
JP6049623B2
(ja)
|
2010-10-22 |
2016-12-21 |
カッパーアールエヌエー，インコーポレイテッド |
α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
AU2011325956B2
(en)
|
2010-11-12 |
2016-07-14 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
WO2012071238A2
(en)
|
2010-11-23 |
2012-05-31 |
Opko Curna Llc |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
|
US10583128B2
(en)
|
2011-09-06 |
2020-03-10 |
Curna, Inc. |
Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
|
|
EP2755674A4
(en)
|
2011-09-12 |
2015-04-08 |
Tau Therapeutics Llc |
ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS
|
|
JP6129844B2
(ja)
|
2011-09-14 |
2017-05-17 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
|
CN118581086A
(zh)
|
2012-01-27 |
2024-09-03 |
比奥马林技术公司 |
用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
EP2825648B1
(en)
|
2012-03-15 |
2018-09-05 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
KR20150030205A
(ko)
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
JP2015523853A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ａｔｐ２ａ２発現を調節するための組成物及び方法
|
|
SG11201407486PA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating utrn expression
|
|
EA201492121A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов гемоглобина
|
|
CA2884608C
(en)
|
2012-09-14 |
2025-05-20 |
Translate Bio Ma, Inc. |
MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
|
|
US10024844B2
(en)
|
2012-12-20 |
2018-07-17 |
Hospital For Special Surgery |
Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
|
|
EA202090946A3
(ru)
|
2013-03-14 |
2021-07-30 |
Сарепта Терапьютикс, Инк. |
Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
|
|
NZ631289A
(en)
|
2013-03-15 |
2017-08-25 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
EP3033422A4
(en)
|
2013-08-16 |
2017-08-02 |
Rana Therapeutics Inc. |
Oligonucleotides targeting euchromatin regions of genes
|
|
PT3049085T
(pt)
|
2013-09-26 |
2021-10-01 |
Beth Israel Deaconess Medical Ct Inc |
Inibidores de sgk1 no tratamento da síndrome do qt longo
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
HRP20181914T1
(hr)
|
2014-03-20 |
2019-01-11 |
Cymabay Therapeutics, Inc. |
Liječenje intrahepatičnih kolestatskih bolesti
|
|
SG11201608077PA
(en)
|
2014-04-11 |
2016-10-28 |
Cymabay Therapeutics Inc |
Treatment of nafld and nash
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
EP3201339A4
(en)
|
2014-10-03 |
2018-09-19 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
|
US10858650B2
(en)
|
2014-10-30 |
2020-12-08 |
The General Hospital Corporation |
Methods for modulating ATRX-dependent gene repression
|
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
|
AU2016334804B2
(en)
|
2015-10-09 |
2022-03-31 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
ES2936400T3
(es)
|
2015-10-22 |
2023-03-16 |
Cavion Inc |
Métodos para tratar el síndrome Angelman
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
ES2882500T3
(es)
|
2015-12-14 |
2021-12-02 |
Cold Spring Harbor Laboratory |
Oligómeros antisentido para el tratamiento del síndrome de Dravet
|
|
EP4678748A2
(en)
|
2015-12-21 |
2026-01-14 |
Novartis AG |
Compositions and methods for decreasing tau expression
|
|
WO2018152317A1
(en)
|
2017-02-15 |
2018-08-23 |
Cavion, Inc. |
Calcium channel inhibitors
|
|
KR102654466B1
(ko)
|
2017-04-26 |
2024-04-08 |
카비온, 인코포레이티드 |
기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법
|
|
CN107460219B
(zh)
*
|
2017-07-24 |
2020-04-10 |
武汉大学 |
一种差异核酸酶切方法及其在LC-MS法检测mRNA内部修饰中的应用
|
|
SI3673080T1
(sl)
|
2017-08-25 |
2024-03-29 |
Stoke Therapeutics, Inc. |
Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni
|
|
WO2019213525A1
(en)
|
2018-05-04 |
2019-11-07 |
Stoke Therapeutics, Inc. |
Methods and compositions for treatment of cholesteryl ester storage disease
|
|
TW202602439A
(zh)
|
2018-10-03 |
2026-01-16 |
美商卡凡恩公司 |
以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
|
|
KR20210134003A
(ko)
|
2019-02-27 |
2021-11-08 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 안티센스 올리고머
|
|
BR112022022889A2
(pt)
|
2020-05-11 |
2023-04-04 |
Stoke Therapeutics Inc |
Oligômeros antissentido de opa1 para tratamento de condições e doenças
|